A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Omalizumab (Primary)
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 19 Nov 2020 Results estimating the impact of omalizumab on paid and unpaid work presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 11 Dec 2019 According to a Novartis Pharmaceuticals media release, Novartis Receives Approval for Additional Application of Zolea the World's First Antibody for Seasonal Allergic Rhinitis based on results of this trial.
- 04 Oct 2019 Results presented in a Novartis Media Release.